Xbrane Biopharma AB 2023 IR
The report highlights Xbrane Biopharma's transition into a commercial-stage company in 2023 with the European launch of its first biosimilar, Ximluci, which generated SEK 210 million in income and treated approximately 4,000 patients. The company focused its development portfolio on Xdivane and BIIB801, implementing a cost-saving scheme expected to yield SEK 50 million in annual savings. Xbrane also expanded its intellectual property portfolio, filing 36 new patent applications and receiving approval for three patents. Additionally, the company joined the UN Global Compact and maintained its Great Place to Work certification for the third consecutive year.
Company: Xbrane Biopharma AB
Sector: Health Care
Country: Sweden
Year: 2023
Type: IR
Pages: 96
Xbrane Biopharma AB
Annual And Sustainability Report
The report highlights Xbrane Biopharma's transition into a commercial-stage company in 2023 with the European launch of its first biosimilar, Ximluci, which generated SEK 210 million in income and treated approximately 4,000 patients. The company focused its development portfolio on Xdivane and BIIB801, implementing a cost-saving scheme expected to yield SEK 50 million in annual savings. Xbrane also expanded its intellectual property portfolio, filing 36 new patent applications and receiving approval for three patents. Additionally, the company joined the UN Global Compact and maintained its Great Place to Work certification for the third consecutive year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees